Pozen loses latest bid for FDA approval of MT100

Pozen lost another round with the FDA in its quest to gain approval for the migraine drug MT100. A special agency committee decided that the clinical data for the drug does not warrant exposing patients to tardive dyskinesia, involuntary movements of the tongue and mouth. The FDA issued a nonapprovable letter for MT100 more than a year ago, which at the time caused an immediate sell-off of Pozen stock that cut its $17 price in half. The company's CEO maintained that Pozen hadn't lost any ground on the drug, noting the earlier rejection. But investors weren't as confident. Pozen stock slipped 5 percent yesterday, closing at $7.97.

- read this story from Localtechwire for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.